47Indexed trials
mesh condition
Neoplasms
Intelligence
Neoplasms intelligence: 47 indexed trials, 10 recruiting studies, 44 sponsors across 26 countries.
10Recruiting
44Sponsors
26Countries
Leading sponsors
GlaxoSmithKline20 recruiting
Medical University of South Carolina22 recruiting
Merck Sharp & Dohme LLC21 recruiting
Anova Enterprises, Inc10 recruiting
Central Hospital, Nancy, France10 recruiting
Centre Hospitalier Emile Roux11 recruiting
CHU de Reims10 recruiting
Constantinos Hadjipanayis10 recruiting
Eisai Inc.10 recruiting
Eli Lilly and Company10 recruiting
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau10 recruiting
Colombian Foundation for Epilepsy and Neurological Disease10 recruiting
Geographic activity
United States23trials
Spain4trials
France4trials
United Kingdom3trials
Turkey (Türkiye)3trials
Netherlands3trials
Chile2trials
Hong Kong2trials
Denmark2trials
Colombia1trials
Greece1trials
China1trials
Leading interventions
Pembrolizumab2trials
Behavioral Activation Therapy App1trials
Cognitive-behavioral therapy for worry, uncertainty & insomnia1trials
Carboplatin1trials
Cetuximab1trials
Cisplatin1trials
Brain Health Workshop (BHW)1trials
Control group1trials
Dexmedetomidine1trials
Digital storytelling1trials
Donepezil hydrochloride1trials
AZD74511trials
Methodology note
This entity is derived from structured ClinicalTrials.gov conditions and/or MeSH normalization. Counts reflect the current NeuroRisk indexed corpus and are not guaranteed exhaustive global totals.